Antigen Preparation
A recombinant protein of human CD52
Background
"CD52 is a small glycoprotein containing a large N-linked carbohydrate moiety that was originally identified as the target of the lymphocyte-depleting CAMPATH rat monoclonal antibody. CD52 is highly expressed on lymphoid cells, especially memory CD4+ T cells and B cells, and on myeloid cells, particularly CD16+ dendritic cells and monocytes. Soluble CD52 inhibits Toll-like receptor and tumor necrosis factor receptor signaling to limit activation of NF-κB and thereby suppress the production of inflammatory cytokines by macrophages, monocytes and dendritic cells. At higher concentrations, soluble CD52 depletes the short-lived pro-survival protein MCL-1, contributing to activation of the BH3-only proteins BAX and BAK to cause intrinsic apoptotic cell death. Campath-1H (alemtuzumab) is a humanized antibody against CD52 currently approved for chronic lymphocytic leukemia (CLL) therapy. The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis"
Applications/Suggested Working Dilutions
|
|
|
Immunoprecipitation
2-5 µg/ml
|
|
Flow cytometry
0.5-5 µg/106 cells
|